Entrust Financial’s ImmunityBio IBRX Stock Holding History

Entrust Financial’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-595	Closed	-$4.56K	–	456
2026 Q1	$4.56K	Buy	+595	New	+$4.07K	﹤0.01%	362

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Entrust Financial's IBRX Position: Q2 2026 in Review

Entrust Financial sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 595 shares — an estimated $4.56K sold.

Entrust Financial first reported a position in IBRX in Q1 2026 and held it in 1 quarter. The position peaked at $4.56K in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Entrust Financial reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
Entrust Financial sold 595 ImmunityBio shares in Q2 2026, an estimated $4.56K.
Entrust Financial first reported a position in ImmunityBio in Q1 2026 and held it in 1 quarter.
Entrust Financial's ImmunityBio position peaked at $4.56K in Q1 2026.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Entrust Financial's 13F filing for Q2 2026, filed 20 Jul 2026.